Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Travere Therapeutics
Travere Therapeutics
(TVTX)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Kolbam
Cholic acid
2015-11-20
Zellweger syndrome
,
Inborn errors metabolism
Syntocinon
Oxytocin
1982-01-01
Postpartum hemorrhage
Filspari
Sparsentan
2023-02-17
2030
Proteinuria
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Sparsentan
healthy volunteers/patients
,
neoplasms
,
nephrotic syndrome
,
iga vasculitis
,
vasculitis
,
hereditary nephritis
,
lipoid nephrosis
,
cardiovascular diseases
,
anti-neutrophil cytoplasmic antibody-associated vasculitis
,
glomerulonephritis
,
immune system diseases
,
autoimmune diseases
,
iga glomerulonephritis
,
focal segmental glomerulosclerosis
,
kidney diseases
,
proteinuria
,
kidney transplantation
Pegtibatinase
homocystinuria
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use